Last updated:
24 March 2017
February 2017 - Application from Algalo Industries for an opinion on the substantial equivalence of a dried biomass and oleoresin product from H.pluvialis using supercritical carbon dioxide. Under Evaluation

Astaxanthin is a carotenoid which is found in Haematococcus pluvialis. The microalgae is part of the diet of fish or crustaceans (such as salmon and shrimps) and is responsible for the pink coloration of their flesh.

This application if for use in food supplements at a maximum consumption of 4mg/day

Regulation (EC) 258/97 makes provision for novel foods or ingredients that are substantially equivalent to an existing product to be placed on the market once the applicant has informed the European Commission. In all cases to date, the Commission has required that the applicant first obtains an opinion on substantial equivalence from a Member State. Algalo Industries has requested such an opinion from the UK Competent Authority on the equivalence of its dry biomass and oleoresin product from Haematococcus pluvialis to an existing product on the market produced by AstaReal AB. AstaReal AB has marketed its Astaxanthin product in the EU since at least 1995.

On 23 June, the EU referendum took place and the people of the United Kingdom voted to leave the European Union. Until exit negotiations are concluded the UK remains a full member of the European Union and all the rights and obligations of EU membership remain in force. During this period the Government will continue to negotiate, implement and apply EU legislation.  The Government, under the Prime Minister, has begun negotiations to exit the EU. The outcome of these negotiations will determine what arrangements apply in relation to EU legislation and funding in future once the UK has left the EU.

Any comments on this opinion should be emailed to the ACNFP Secretariat at  by 12 July 2017. The comments will be passed to the Committee for consideration in finalising its assessment of this novel food ingredient.

All views/comments received by the FSA will be made available for public examination as part of the Committees consideration of the application. If you would prefer your comments not to be made publically available, please indicate this in your response.